Mobius Theraputics™ Announces Assignment of HCPCS Code for Mitosol®
Published: Nov 08, 2012
ST. LOUIS, MO--(Marketwire - November 08, 2012) -
Mobius Therapeutics(TM), LLC
"This is an important milestone for Mobius Therapeutics, and we are very pleased that CMS has issued a J-code for Mitosol®," said Ed Timm, Chief Executive Officer and Founder of Mobius Therapeutics, LLC. "While it may take up to three months for the J-code to be loaded into the entire payer system, the J-code facilitates more rapid reimbursement for providers. Mitosol is manufactured under cGMP controls and provides assured dosing concentration with consistent potency and sterility. In light of the on-going concerns related to the sterility and quality assurance of sterile filled medications, Mitosol's quality manufacturing and convenience helps providers and patients with peace of mind."
J-codes are part of the Healthcare Common Procedure Coding System (HCPCS), and used by providers to identify medical products to facilitate reimbursement.
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.
Mobius Therapeutics, LLC
The Vandiver Group, Inc.